Cargando…
Suppression of Serum Interferon‐γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus
OBJECTIVE: In a previously reported phase II randomized, placebo‐controlled, interventional trial, we demonstrated that treatment with ustekinumab, an anti–interleukin‐12 (IL‐12)/IL‐23 p40 neutralizing monoclonal antibody, improved global and organ‐specific measures of disease activity in patients w...
Autores principales: | Cesaroni, Matteo, Seridi, Loqmane, Loza, Matthew J., Schreiter, Jessica, Sweet, Kristen, Franks, Carol, Ma, Keying, Orillion, Ashley, Campbell, Kim, M. Gordon, Robert, Branigan, Patrick, Lipsky, Peter, van Vollenhoven, Ronald, Hahn, Bevra H., Tsokos, George C., Chevrier, Marc, Rose, Shawn, Baribaud, Frédéric, Jordan, Jarrat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986128/ https://www.ncbi.nlm.nih.gov/pubmed/33010188 http://dx.doi.org/10.1002/art.41547 |
Ejemplares similares
-
Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus
por: van Vollenhoven, Ronald F, et al.
Publicado: (2022) -
Biological impact of iberdomide in patients with active systemic lupus erythematosus
por: Lipsky, Peter E, et al.
Publicado: (2022) -
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022) -
Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
por: Doria, A., et al.
Publicado: (2018) -
Cumulative Corticosteroid Dose Over Fifty‐Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials
por: van Vollenhoven, Ronald F., et al.
Publicado: (2016)